Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus Aureus by pharmacokinetic/pharmacodynamic analysis

References

• Rothberg MB. Community-acquired pneumonia. Ann Intern Med. 2022;175(4):ITC49–ITC64. doi: 10.7326/AITC202204190.
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Nowak M, Geriak M. Omadacycline in treating community-based infections: a review and expert perspective. Expert Rev Anti Infect Ther. 2023;21(3):255–265. doi: 10.1080/14787210.2023.2174100.
   PubMed Web of Science ®Google Scholar
• Peyrani P, Mandell L, Torres A, et al. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. Expert Rev Respir Med. 2019;13(2):139–152. doi: 10.1080/17476348.2019.1562339.
   PubMed Web of Science ®Google Scholar
• LaPensee K, Mistry R, Lodise T. Budget impact of omadacycline for the treatment of patients with community-acquired bacterial pneumonia in the United States from the hospital perspective. Am Health Drug Benefits. 2019;12(1-Supplement 1):S1–S12.
   PubMedGoogle Scholar
• Eshwara VK, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: an update. Indian J Med Res. 2020;151(4):287–302. doi: 10.4103/ijmr.IJMR_1678_19.
   PubMed Web of Science ®Google Scholar
• Dougherty JA, Sucher AJ, Chahine EB, et al. Omadacycline: a new tetracycline antibiotic. Ann Pharmacother. 2019;53(5):486–500. doi: 10.1177/1060028018818094.
   PubMed Web of Science ®Google Scholar
• Leviton IM, Amodio-Groton M. Omadacycline oral dosing and pharmacokinetics in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. Clin Drug Investig. 2022;42(3):193–197. doi: 10.1007/s40261-022-01119-9.
   PubMed Web of Science ®Google Scholar
• Chopra T, Sandhu A, Theriault N, et al. Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Future Microbiol. 2020;15(14):1319–1333. doi: 10.2217/fmb-2020-0182.
   PubMed Web of Science ®Google Scholar
• Flarakos J, Du Y, Gu H, et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. Xenobiotica. 2017;47(8):682–696. doi: 10.1080/00498254.2016.1213465.
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Hammel JP, Lakota EA, et al. Pharmacokinetic-pharmacodynamic target attainment analyses evaluating omadacycline dosing regimens for the treatment of patients with community-acquired bacterial pneumonia arising from Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother. 2023;67(4):e0221321. doi: 10.1128/aac.02213-21.
   PubMed Web of Science ®Google Scholar
• Lakota EA, Van Wart SA, Trang M, et al. Population pharmacokinetic analyses for omadacycline using phase 1 and 3 data. Antimicrob Agents Chemother. 2020;64(7):e02263-19. doi: 10.1128/AAC.02263-19.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Huband MD, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY antimicrobial surveillance program, 2019. J Glob Antimicrob Resist. 2021;27:337–351. doi: 10.1016/j.jgar.2021.09.011.
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Zhao M, Marchillo K, et al. In vivo pharmacodynamic evaluation of omadacycline against Staphylococcus aureus in the neutropenic mouse pneumonia model. Antimicrob Agents Chemother. 2020;64(2):e02058-19. doi: 10.1128/AAC.02058-19.
   PubMed Web of Science ®Google Scholar
• Ni W, Li G, Zhao J, et al. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae. Infect Dis. 2018;50(7):507–513. doi: 10.1080/23744235.2018.1423703.
   PubMed Web of Science ®Google Scholar
• Kuti JL, Nicolau DP. Making the most of surveillance studies: summary of the OPTAMA program. Diagn Microbiol Infect Dis. 2005;53(4):281–287. doi: 10.1016/j.diagmicrobio.2005.10.004.
   PubMed Web of Science ®Google Scholar
• Yang H, Huang Z, Chen Y, et al. Pharmacokinetics, safety and pharmacokinetics/pharmacodynamics analysis of omadacycline in Chinese healthy subjects. Front Pharmacol. 2022;13:869237. doi: 10.3389/fphar.2022.869237.
   PubMed Web of Science ®Google Scholar
• Bhavnani S, Hammel J, Lakota E, et al. Assessment of pharmacokinetic-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) [abstract no P1944 plus poster]. 29th European Congress of Clinical Microbiology and Infectious Disease; 13–16 April 2019; Amsterdam.
   Google Scholar
• Zhou J, Ledesma KR, Chang KT, et al. Pharmacokinetics and pharmacodynamics of minocycline against Acinetobacter baumannii in a neutropenic murine pneumonia model. Antimicrob Agents Chemother. 2017;61(5):e02371-16. doi: 10.1128/AAC.02371-16.
   PubMed Web of Science ®Google Scholar
• Zhao M, Lepak AJ, Marchillo K, et al. In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model. Antimicrob Agents Chemother. 2017;61(7):e00250-17. doi: 10.1128/AAC.00250-17.
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Zhao M, Marchillo K, et al. In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model. Antimicrob Agents Chemother. 2017;61(5):e02368-16. doi: 10.1128/AAC.02368-16.
   PubMed Web of Science ®Google Scholar
• VanScoy BD, Lakota EA, Conde H, et al. Pharmacokinetic-pharmacodynamic characterization of omadacycline against Haemophilus influenzae using a one-compartment in vitro infection model. Antimicrob Agents Chemother. 2020;64(6):e02265-19. doi: 10.1128/AAC.02265-19.
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Zhao M, Marchillo K, et al. In vivo pharmacodynamics of omadacycline against Staphylococcus aureus in the neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2019;63(7):e00624-19. doi: 10.1128/AAC.00624-19.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Huband MD, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018. Antimicrob Agents Chemother. 2020;64(5):e02488-19. doi: 10.1128/AAC.02488-19.
   PubMed Web of Science ®Google Scholar
• Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517–527. doi: 10.1056/NEJMoa1800201.
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Tzanis E, Curran M, et al. Early clinical response in community-acquired bacterial pneumonia: from clinical endpoint to clinical practice. Clin Infect Dis. 2019;69(Suppl 1):S33–S39. doi: 10.1093/cid/ciz397.
   PubMedGoogle Scholar